Sudeep Pharma had a robust market debut on Friday, with its stock listing at a 24% premium over the IPO price of Rs 593. The company opened at Rs 733.95 on the BSE and Rs 730 on the NSE, reflecting investor willingness to pay more for a manufacturer of specialty chemicals and pharmaceutical ingredients with a global presence.
Prior to the listing, there was strong demand for the IPO as indicated by the company’s shares trading at a premium of over 20% in the unlisted market. The IPO, which raised Rs 895 crore, was oversubscribed by an impressive 93.72 times, attracting bids worth more than Rs 58,700 crore from nearly 29.9 lakh applications. Furthermore, Sudeep Pharma raised Rs 268.5 crore from anchor investors before the IPO, showcasing institutional confidence in the company.
Sudeep Pharma specializes in manufacturing mineral-based excipients and specialty ingredients used in various medical and nutritional products. The company supplies a range of compounds such as calcium, magnesium, sodium, potassium, zinc, and iron to major pharmaceutical and nutraceutical firms in India and abroad. A significant portion of the IPO proceeds will be utilized to acquire new machinery and expand production capacity at its key facility in Nandesari, Gujarat.
Experts note the increasing global demand for excipients and nutritional ingredients, driven by the growth of generic drug manufacturing, rising nutraceutical consumption, and the complexity of formulations. Companies like Sudeep Pharma, operating in niche markets and maintaining strong relationships with pharmaceutical giants, typically command high valuations in the industry.
Despite the successful market debut, analysts are cautious about short-term challenges. Margins in the specialty chemicals and pharmaceutical inputs sector are sensitive to fluctuations in raw material prices. Intensifying competition from both domestic and international suppliers, along with the challenges of global demand cycles and regulatory compliance for export-oriented businesses, pose risks.
Shivani Nyati, Head of Wealth at Swastika Investmart Ltd., advised investors to consider booking partial profits following the strong listing, while suggesting long-term investors hold onto their shares with a disciplined stop loss strategy. The future performance of Sudeep Pharma will hinge on its ability to execute expansion plans efficiently, maintain margins in a volatile input cost environment, and capitalize on the increasing global demand for high-quality excipients.
Investors are keen to monitor the company’s quarterly results closely to assess whether the premium valuation is justified. The market has given Sudeep Pharma a strong start, but its future trajectory will depend on various operational factors and market conditions.
Please note that the opinions expressed in this article are solely those of the experts/brokerages mentioned and do not represent the views of the India Today Group. It is advisable to seek guidance from a qualified financial advisor before making any investment decisions.